Variates of Survival in Metastatic Uveal Melanoma

Rietschel, Petra; Panageas, Katherine S.; Hanlon, Christine; Patel, Ami B.; Abramson, David H.; Chapman, Paul B.

doi:10.1200/jco.2005.02.6534

Cited by 267 publications

(241 citation statements)

References 8 publications

Supporting

Mentioning

225

Contrasting

Unclassified

Order By: Relevance

“…[1][2][3] When liver metastases develop, the prognosis is poor and life expectancy reduces to less than 6 months in the absence of treatment. 4 No adjuvant therapy has proven efficacy for the prevention of metastases following ocular treatment and only minimal improvements in disease-free survival have been observed with intra-arterial chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie

Mariani

Piperno‐Neumann

Servois

et al. 2009

European Journal of Surgical Oncology (EJSO)

173

161

View full text Add to dashboard Cite

Please cite this article as: Mariani P., Piperno-Neumann S., Servois V., Berry M.G., Dorval T., Plancher C., Couturier J., Levy-Gabriel C., Lumbroso-Le Rouic L., Desjardins L., Salmon R.J. Surgical management of liver metastases from uveal melanoma:16 years'experience at the Institut Curie., European Journal of Surgical Oncology (2009Oncology ( ), doi: 10.1016Oncology ( /j.ejso.2009 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Introductionmentioning

confidence: 99%

Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie

Mariani

Piperno‐Neumann

Servois

et al. 2009

European Journal of Surgical Oncology (EJSO)

173

161

View full text Add to dashboard Cite

show abstract

“…About half of the UM patients eventually develop hematogenous metastasis, with liver metastasis being the most common form. Without proper treatment, most patients with metastasis will die within a short period of time (6−8 months) (216). According to the Collaborative Ocular Melanoma Study (COMS), a large multicenter study participated by 43 clinical ophthalmic centers in North America, the median survival was only 3.6 months among UM patients with confirmed metastasis, and the 5-year cumulative survival rate was only 1% (217).…”

Section: Biological Characteristicsmentioning

confidence: 99%

Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)

et al. 2016

View full text Add to dashboard Cite

“…The natural history of uveal melanoma is characterized by the frequent development of metastases, with over 50% of patients developing metastatic disease at any time from the initial diagnosis of the primary to several decades later (2,(16)(17)(18)(19)(20)(21). A broad spectrum of therapies, including systemic therapies (22), hepatic artery infusion of chemotherapy, hepatic embolization, and metastastectomy, have been used to treat patients with metastatic uveal melanoma.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Implications of the Emerging Molecular Biology of Uveal Melanoma

Patel

Smyth

Chapman

et al. 2011

Clinical Cancer Research

Self Cite

106

View full text Add to dashboard Cite

Uveal melanoma represents the most common primary intraocular malignancy in adults. Although uveal and cutaneous melanomas both arise from melanocytes, uveal melanoma is clinically and biologically distinct from its more common cutaneous counterpart. Metastasis occurs frequently in this disease, and once distant spread occurs, outcomes are poor. No effective systemic therapies are currently available; however, recent advances in our understanding of the biology of this rare and devastating disease, combined with the growing availability of targeted agents, which can be used to rationally exploit these findings, hold the promise for novel and effective therapies in the foreseeable future. Herein, we review our rapidly growing understanding of the molecular biology of uveal melanoma, including the pathogenic roles of GNAQ (guanine nucleotide binding protein q polypeptide)/11, PTEN (phosphatase and tensin homolog), IGF (insulin-like growth factor)/IGF-1 receptor, MET (hepatocyte growth factor), BAP1 [breast cancer 1, early onset (BRCA1)-associated protein-1], and other key molecules, potential therapeutic strategies derived from this emerging biology, and the next generation of recently initiated clinical trials for the treatment of advanced uveal melanoma.

show abstract

Variates of Survival in Metastatic Uveal Melanoma

Cited by 267 publications

References 8 publications

Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie

Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie

Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)

Therapeutic Implications of the Emerging Molecular Biology of Uveal Melanoma

Contact Info

Product

Resources

About